HeartBeam (Nasdaq:BEAT) announced today that it made significant developments in the AI applied to its proprietary ECG technology.
Santa Clara, California-based HeartBeam develops its proprietary vectorelectrocardiography (VECG) technology. The company aims to provide diagnostic and prognostic insights about cardiac health beyond what standard 12-lead ECGs provide.
HeartBeam’s VECG technology collects 3D signals of the heart and converts them into an easy-to-interpret 12-lead ECG. The company designed it for use with portable, patient-friendly devices. Its first planned application comes in the form of the AIMIGo credit card-sized device.
The company leverages AI to analyze data-rich signals captured by the VECG, hoping to improve diagnostic accuracy and extract unique information. That includes complex heart rhythms, subtle signs of deteriorating health and potentially missed cardiac events.
According to a news release, the data collected c…